Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquisitionAnnouncedBy |
gptkb:AbbVie
|
| gptkbp:acquisitionAnnouncementDate |
December 2023
|
| gptkbp:CEO |
gptkb:Tony_Coles
|
| gptkbp:clinicalTrialPhase |
gptkb:Parkinson's_disease
epilepsy schizophrenia Alzheimer's disease psychosis |
| gptkbp:focusesOn |
neurology
psychiatry central nervous system disorders |
| gptkbp:foundedYear |
2018
|
| gptkbp:founder |
gptkb:Pfizer
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cerevel Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Bain_Capital
|
| gptkbp:keyProductCandidates |
gptkb:CVL-871
gptkb:darigabat gptkb:emraclidine gptkb:tavapadon |
| gptkbp:numberOfEmployees |
approximately 300 (as of 2023)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:CERE
active (as of early 2024) |
| gptkbp:website |
https://www.cerevel.com/
|
| gptkbp:bfsParent |
gptkb:Bain_Capital
|
| gptkbp:bfsLayer |
5
|